Real-World Treatment Patterns and Cost of Care in US Ovarian Cancer Patients Undergoing BRCA Testing
Approximately one-fourth of patients received BRCA testing. Disparities existed between those who received testing and those who did not. Patients who were tested had higher costs than those who were not; this difference was driven mostly by ambulatory visits and pharmacy costs, potentially due to increased clinical encounters and higher costs of targeted treatments.
Authors
- Srujitha Marupuru (ORCID: https://orcid.org/0000-0003-3786-2846)
- Sarah Aurit
- Gretchen Hultman
- Gieira S. Jones (ORCID: https://orcid.org/0000-0001-9537-6470)
- Noah Webb (ORCID: https://orcid.org/0009-0009-8379-2050)
- Desiree Hall
- Kristin J. Moore (ORCID: https://orcid.org/0000-0003-2179-6565)
- Zhu Yong
Institutions
- Merck Biopharma Co., Ltd. (Japan) (JP)
- Optum (United States) (US)
- Optimum Therapeutics (United States) (US)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2025-08-26
- DOI
- https://doi.org/10.36469/001c.142444
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00